Abbott Laboratories logo

Abbott Laboratories (ABT)

Market Closed
29 Apr, 20:00
NYSE NYSE
$
130. 50
+0.97
+0.75%
$
206.31B Market Cap
36.49 P/E Ratio
2.2% Div Yield
4,315,300 Volume
4.44 Eps
$ 129.53
Previous Close
Day Range
128.8 131.27
Year Range
99.71 141.23

Summary

ABT closed today higher at $130.5, an increase of 0.75% from yesterday's close, completing a monthly decrease of -5.55% or $7.67. Over the past 12 months, ABT stock gained 14.79%.
ABT pays dividends to its shareholders, with the most recent payment made on Feb 14, 2025. The next announced payment will be in In 2 weeks on May 15, 2025 for a total of $0.59.
The last earnings report, released on Apr 15, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track ABT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

ABT Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information

Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data for healthcare organizations Integration empowers U.S. clinicians to enhance patient care by incorporating Libre's data directly into their workflows ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology1, today announced that it has entered a first-of-its-kind agreement to integrate data from its world-leading1 Libre CGM systems directly into Epic's electronic health record systems in the U.S. The collaboration aims to improve workflow efficiency for providers through Epic's Aura software, which brings health systems together with diagnostics labs and medical device manufacturers.

Prnewswire | 18 hours ago
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Voltâ„¢ PFA System for Patients with AFib

New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Voltâ„¢ PFA System for Patients with AFib

Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Voltâ„¢ PFA System The 12-month results of the Volt CE Mark Study confirm the long-term safety and efficacy of the Volt PFA System The data were presented at the 2025 Heart Rhythm Society (HRS) annual meeting ABBOTT PARK, Ill., April 26, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Voltâ„¢ PFA System for the treatment of atrial fibrillation (AFib).

Prnewswire | 3 days ago
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?

Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?

With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.

Zacks | 4 days ago

Abbott Laboratories (ABT) FAQ

What is the stock price today?

The current price is $130.50.

On which exchange is it traded?

Abbott Laboratories is listed on NYSE.

What is its stock symbol?

The ticker symbol is ABT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 206.31B.

Has Abbott Laboratories ever had a stock split?

No, there has never been a stock split.

Abbott Laboratories Profile

Medical Devices Industry
Healthcare Sector
Mr. Robert B. Ford CEO
NYSE Exchange
US0028241000 ISIN
United States Country
114,000 Employees
15 Apr 2025 Last Dividend
2 Jan 2013 Last Split
13 Jan 1978 IPO Date

Overview

Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.

Products and Services

Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains:

  • Generic Pharmaceuticals: Includes treatments for pancreatic exocrine insufficiency, irritable bowel syndrome, biliary spasm, intrahepatic cholestasis, depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease, vestibular vertigo, pain, fever, inflammation, migraine, anti-infective clarithromycin, influenza vaccine, and colon rhythm regulation products.
  • Diagnostic Products: Offers laboratory and transfusion medicine systems in areas such as immunoassay, clinical chemistry, hematology, and transfusion. Includes molecular diagnostics for DNA and RNA processing and detection of infectious agents, point-of-care systems, blood gas testing cartridges, rapid diagnostics, molecular point-of-care testing for several diseases, cardiometabolic tests, drug and alcohol tests, remote patient monitoring, consumer self-tests, and laboratory automation and informatics solutions.
  • Nutritional Products: Provides nutritional products for both pediatric and adult use, catering to the specific dietary needs of different age groups and health conditions.
  • Medical Devices: Offers a wide array of devices for the treatment of cardiovascular diseases, including rhythm management, electrophysiology, heart failure, vascular, and structural heart devices. Additionally, the company develops diabetes care products such as blood glucose monitoring systems, along with neuromodulation devices for managing chronic pain and movement disorders.

Contact Information

Address: 100 Abbott Park Road
Phone: 224 667 6100